Clinical trial
A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies
NCT02678260 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 19, 2016
- Completion date
- September 1, 2017
- Enrollment
- 18 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignancies